Back to results
US 2019/0315812 A1Published application
Modified meningococcal fhbp polypeptides
AssigneeGlaxosmithkline Biologicals SA
InventorsMatthew BOTTOMLEY, Enrico MALITO, Manuele MARTINELLI
Life of this patent
Estimating the term…
Abstract
Modified meningococcal fHbp polypeptides with increased stability.
Claims11
1-15. (canceled)
A mutant v3 fHbp polypeptide comprising an amino acid sequence having at least 90% sequence identity to SEQ ID NO:
- 17 and containing an amino acid residue corresponding to residue S32 of SEQ ID NO:
- 17 that has been substituted with any other amino acid, and further comprising a substitution at a position corresponding to L126 of SEQ ID NO:
- 17.
A polypeptide comprising a sequence selected from:
- (a) SEQ ID NO:
- 44,
- (b) SEQ ID NO:
- 44 with 1, 2, 3, 4, or 5 single amino acid substitutions, deletions and/or insertions at positions other than residue V32 and R126, wherein the polypeptide can elicit antibodies which bind to a meningococcal fHbp polypeptide consisting of the amino acid sequence of SEQ ID NO:
- 40;
- and
- (c) a fHbp v3 amino acid sequence, wherein the v3 amino acid sequence is identical to a v3 wild-type amino acid sequence except for a mutation at the amino acid position corresponding to Leu-126 of SEQ ID NO:
- 17, provided that the mutation is not a substitution to alanine.
5 more elements
Dependencies are inferred from the claim text.